Company to pursue path toward U.S. and European approvals; Type C meeting with FDA confirmed for Q2 2023; plans in place to meet with multiple European regulatory authorities
Adial in discussions with potential pharma partners
Conference call to be held at 8:15 a.m. EST tomorrow
The Company will host a conference call at 8:15 a.m. Eastern Time tomorrow, March 7, 2023, to provide an update on its regulatory and partnering strategy for the United States and Europe. The company will also present and discuss the findings from its subgroup analysis of ONWARD data.
A live audio webcast of the conference call and accompanying slide presentation may be accessed at https://www.webcaster4.com/Webcast/Page/2463/47766, or on the investor relations section of the company’s website at https://www.adial.com/news-events/. The conference call will also be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 737117. Participants that dial into the call may obtain the accompanying slides on the investor relations section of the Company’s website at https://www.adial.com/news-events/.
A webcast replay will be available on the investor relations section of the company’s website at https://www.adial.com/news-events/ through March 7, 2024. A telephone replay of the call will be available approximately one hour following the call, through March 21, 2023, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering access code 47766.
https://finance.yahoo.com/news/adial-pharmaceuticals-provides-regulatory-strategy-211900556.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.